ACAD Head of R&D Departs, Will Serve as Consultant Through Year-End

Acadia Pharmaceuticals confirmed that Elizabeth H.Z. Thompson, Ph.D., Executive Vice President and Head of Research and Development, has officially retired from the company. Her departure was effective October 23, 2026, and the company is actively searching for her successor.

Key Details

• Departure: Dr. Thompson's employment and role as Head of R&D concluded on October 23, 2026, following a previously announced retirement plan.
• Transition: She will be retained as a consultant to provide limited services to the company through December 31, 2026.
• Succession: The company is currently in the process of identifying a replacement for the Head of Research and Development position.